This recombinant monoclonal antibody is developed as a research-grade biosimilar to Rademikibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two critical cytokines in type 2 inflammatory responses. Upon ligand binding, IL4R initiates JAK-STAT signaling pathways that regulate immune cell differentiation, IgE production, and the expression of inflammatory mediators. Dysregulated IL4R signaling plays a central role in allergic diseases, atopic dermatitis, asthma, and various type 2 inflammatory conditions.
Rademikibart is a therapeutic monoclonal antibody designed to block IL4R signaling by preventing IL-4 and IL-13 from binding to their receptor complexes. This biosimilar antibody provides researchers with a valuable tool for investigating IL4R-mediated pathways, studying type 2 immunity mechanisms, and exploring therapeutic interventions for allergic and inflammatory disorders. It supports investigations into cytokine receptor biology, immune regulation, and the development of targeted immunomodulatory strategies.
Email: support@cusabio.com
Distributors Worldwide